{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:15:39Z","timestamp":1791976539493,"version":"4.4.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Pediatr"],"DOI":"10.1001\/jamapediatrics.2020.5199","type":"journal-article","created":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T16:36:03Z","timestamp":1608568563000},"page":"e205199","source":"Crossref","is-referenced-by-count":53,"title":["Association of Childhood Growth Hormone Treatment With Long-term Cardiovascular Morbidity"],"prefix":"10.1001","volume":"175","author":[{"given":"Anders","family":"Tidblad","sequence":"first","affiliation":[{"name":"Division of Pediatric Endocrinology, Department of Women\u2019s and Children\u2019s Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bottai","sequence":"additional","affiliation":[{"name":"Unit of Biostatistics, Department of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle","family":"Kieler","sequence":"additional","affiliation":[{"name":"Centre for Pharmacoepidemiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Albertsson-Wikland","sequence":"additional","affiliation":[{"name":"Department of Physiology\/Endocrinology, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"S\u00e4vendahl","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology, Department of Women\u2019s and Children\u2019s Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"poi200081r1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000316130","article-title":"Current indications for growth hormone therapy for children and adolescents.","volume":"18","author":"Richmond","year":"2010","journal-title":"Endocr Dev"},{"issue":"2","key":"poi200081r2","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1210\/er.2008-0027","article-title":"Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects.","volume":"30","author":"M\u00f8ller","year":"2009","journal-title":"Endocr Rev"},{"issue":"2","key":"poi200081r3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ecl.2012.04.017","article-title":"Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes.","volume":"41","author":"Clemmons","year":"2012","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"3","key":"poi200081r4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/cen.2008.69.issue-3","article-title":"The GH-IGF-I axis and the cardiovascular system: clinical implications.","volume":"69","author":"Colao","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"poi200081r5","first-page":"1021","article-title":"The cardiovascular system in growth hormone excess and growth hormone deficiency.","volume":"35","author":"Lombardi","year":"2012","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"poi200081r6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/CRD.0b013e318248a3e1","article-title":"Growth hormone and the cardiovascular system.","volume":"20","author":"Palmeiro","year":"2012","journal-title":"Cardiol Rev"},{"issue":"14","key":"poi200081r7","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.jacc.2014.03.063","article-title":"Fasting levels of high-sensitivity growth hormone predict cardiovascular morbidity and mortality: the Malm\u00f6 Diet and Cancer study.","volume":"64","author":"Hallengren","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"poi200081r8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000502231","article-title":"Diagnosis, genetics, and therapy of short stature in children: a Growth Hormone Research Society international perspective.","volume":"92","author":"Collett-Solberg","year":"2019","journal-title":"Horm Res Paediatr"},{"issue":"6","key":"poi200081r9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000452150","article-title":"Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency.","volume":"86","author":"Grimberg","year":"2016","journal-title":"Horm Res Paediatr"},{"issue":"2","key":"poi200081r10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-15-0873","article-title":"GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults.","volume":"174","author":"Allen","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"poi200081r11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1210\/jc.2009-0178","article-title":"Long-term safety of recombinant human growth hormone in children.","volume":"95","author":"Bell","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"poi200081r12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/cen.2018.88.issue-4","article-title":"Long-term safety of growth hormone: a combined registry analysis.","volume":"88","author":"Stochholm","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"poi200081r13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1159\/000342640","article-title":"Pharmacological interventions for short stature: pros and cons.","volume":"71","author":"Rosenfeld","year":"2013","journal-title":"Nestle Nutr Inst Workshop Ser"},{"issue":"1","key":"poi200081r14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1210\/jc.2009-2364","article-title":"Growth hormone post-marketing surveillance: safety, sales, and the unfinished task ahead.","volume":"95","author":"Allen","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"poi200081r15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000435856","article-title":"Description of the SAGhE cohort: a large European study of mortality and cancer incidence risks after childhood treatment with recombinant growth hormone.","volume":"84","author":"Swerdlow","year":"2015","journal-title":"Horm Res Paediatr"},{"issue":"2","key":"poi200081r16","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1210\/jc.2011-1995","article-title":"Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study.","volume":"97","author":"Carel","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"poi200081r17","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1212\/WNL.0000000000000737","article-title":"Growth hormone treatment for childhood short stature and risk of stroke in early adulthood.","volume":"83","author":"Poidvin","year":"2014","journal-title":"Neurology"},{"issue":"10","key":"poi200081r18","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1212\/WNL.0000000000001385","article-title":"Growth hormone treatment for childhood short stature and risk of stroke in early adulthood.","volume":"84","author":"Geffner","year":"2015","journal-title":"Neurology"},{"issue":"10","key":"poi200081r19","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1212\/WNL.0000000000001385","article-title":"Growth hormone treatment for childhood short stature and risk of stroke in early adulthood.","volume":"84","author":"Linglart","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"poi200081r20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1210\/jc.2011-3271","article-title":"Long-term therapy with growth hormone: bringing sagacity to SAGHE.","volume":"97","author":"Sperling","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"poi200081r21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cen.2014.81.issue-1","article-title":"Efficacy and safety of growth hormone treatment in adults with growth hormone deficiency: a systematic review of studies on morbidity.","volume":"81","author":"van Bunderen","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"poi200081r22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1210\/jc.2011-2294","article-title":"Long-term surveillance of growth hormone therapy.","volume":"97","author":"Rosenfeld","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"poi200081r23","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1210\/jc.2015-3951","article-title":"Mortality is not increased in recombinant human growth hormone-treated patients when adjusting for birth characteristics.","volume":"101","author":"Albertsson-Wikland","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"poi200081r24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10654-016-0117-y","article-title":"Registers of the Swedish total population and their use in medical research.","volume":"31","author":"Ludvigsson","year":"2016","journal-title":"Eur J Epidemiol"},{"issue":"11","key":"poi200081r25","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","article-title":"The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research.","volume":"24","author":"Ludvigsson","year":"2009","journal-title":"Eur J Epidemiol"},{"issue":"7","key":"poi200081r26","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/(ISSN)1099-1557","article-title":"The new Swedish Prescribed Drug Register\u2014opportunities for pharmacoepidemiological research and experience from the first six months.","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"poi200081r28","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1210\/jc.2011-1215","article-title":"Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? data from the Dutch National Registry of Growth Hormone Treatment in Adults.","volume":"96","author":"van Bunderen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"poi200081r29","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1530\/EJE-11-1028","article-title":"Overall and cause-specific mortality in GH-deficient adults on GH replacement.","volume":"166","author":"Gaillard","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"poi200081r30","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/cen.12611","article-title":"Growth hormone treatment and stroke: should we be concerned? a case for cohort studies.","volume":"82","author":"Hindmarsh","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"poi200081r31","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1210\/jcem.86.9.7815","article-title":"Gender differences in rhGH-induced changes in body composition in GH-deficient adults.","volume":"86","author":"Span","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"17","key":"poi200081r32","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1056\/NEJMoa044160","article-title":"Trajectories of growth among children who have coronary events as adults.","volume":"353","author":"Barker","year":"2005","journal-title":"N Engl J Med"},{"issue":"21","key":"poi200081r33","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1001\/jama.2009.761","article-title":"Timing and tempo of first-year rapid growth in relation to cardiovascular and metabolic risk profile in early adulthood.","volume":"301","author":"Leunissen","year":"2009","journal-title":"JAMA"},{"issue":"6","key":"poi200081r34","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1210\/jc.2005-2778","article-title":"Early development of adiposity and insulin resistance after catch-up weight gain in small-for-gestational-age children.","volume":"91","author":"Ib\u00e1\u00f1ez","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"poi200081r35","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S2213-8587(17)30311-X","article-title":"Cardiovascular risk factors and carotid intima media thickness in young adults born small for gestational age after cessation of growth hormone treatment: a 5-year longitudinal study.","volume":"5","author":"van der Steen","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"poi200081r36","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1530\/EJE-09-0291","article-title":"Cardiovascular risk factors in hypopituitary GH-deficient adults.","volume":"161","author":"Verhelst","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"poi200081r37","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1210\/jc.2003-030840","article-title":"Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials.","volume":"89","author":"Maison","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"poi200081r38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.beem.2017.03.005","article-title":"Cardiovascular alterations in adult GH deficiency.","volume":"31","author":"Di Somma","year":"2017","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"poi200081r39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2337\/dc11-0449","article-title":"Incidence of diabetes mellitus and evolution of glucose parameters in growth hormone-deficient subjects during growth hormone replacement therapy: a long-term observational study.","volume":"35","author":"Luger","year":"2012","journal-title":"Diabetes Care"},{"issue":"1","key":"poi200081r40","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1210\/jc.2012-2940","article-title":"Metabolic profile in growth hormone-deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy.","volume":"98","author":"Claessen","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"poi200081r27","unstructured":"K\u00e4ll\u00e9n B, K\u00e4ll\u00e9n K. The Swedish Medical Birth Register: A Summary of Content and Quality. Socialstyrelsen; 2003. Accessed August 23, 2018. http:\/\/lup.lub.lu.se\/record\/1127699?"}],"container-title":["JAMA Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/articlepdf\/2773797\/jamapediatrics_tidblad_2020_oi_200081_1611604183.25382.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T04:30:13Z","timestamp":1612240213000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2773797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapediatrics.2020.5199","relation":{},"ISSN":["2168-6203"],"issn-type":[{"value":"2168-6203","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,1]]}}}